↓ Skip to main content

Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list

Overview of attention for article published in BMC Health Services Research, April 2016
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list
Published in
BMC Health Services Research, April 2016
DOI 10.1186/s12913-016-1366-x
Pubmed ID
Authors

Katharina Pohl-Dernick, Florian Meier, Renke Maas, Oliver Schöffski, Martin Emmert

Abstract

Several lists of potentially inappropriate medication (PIM) for elderly patients have been developed worldwide in recent years. Those lists intend to reduce prescriptions of drugs that carry an unnecessarily high risk of adverse drug events in elderly patients. In 2010, an expert panel published the PRISCUS list for the German drug market. This study calculates the amount of drug reimbursement for PIM in Germany and potential cost effects from the perspective of statutory health insurance when these are replaced by the substitutes recommended by the PRISCUS list. Register-based data for the 30 top-selling drugs on the PRISCUS list in 2009 for patients greater than or equal to 65 years of age were provided by the Scientific Institute of the German Local Health Care Fund. We calculated the percentage of sales and defined daily doses for patients greater than or equal to 65 years of age compared with the total statutory health insurance population. Reimbursement costs for the recommended substitutions were estimated by considering different scenarios. In 2009, drug reimbursement for the 30 top-selling PIM prescribed to patients greater than or equal to 65 years of age were calculated to be €305.7 million. Prescribing the recommended substitution medication instead of PIM would lead to an increased total reimbursement cost for the German health care system ranging between from €325.9 million to €810.0 million. The results show that the substitution of PIM by medication deemed to be more appropriate for the elderly comes along with additional costs. Consequently, there is no short-term incentive for doing so from a payer perspective. Future studies have to consider the long-term effects and other sectors.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Unknown 55 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 10 18%
Student > Master 6 11%
Student > Doctoral Student 6 11%
Student > Ph. D. Student 5 9%
Other 4 7%
Other 11 20%
Unknown 14 25%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 16 29%
Medicine and Dentistry 11 20%
Nursing and Health Professions 4 7%
Social Sciences 3 5%
Immunology and Microbiology 1 2%
Other 6 11%
Unknown 15 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2017.
All research outputs
#18,566,650
of 22,996,001 outputs
Outputs from BMC Health Services Research
#6,541
of 7,702 outputs
Outputs of similar age
#220,321
of 300,652 outputs
Outputs of similar age from BMC Health Services Research
#82
of 94 outputs
Altmetric has tracked 22,996,001 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 7,702 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,652 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 94 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.